Endothelin (ET) is a recently discovered 21 ... The effects of ET are mediated through interaction with two classes of cell surface receptors. The type A receptor (ET-A) has been associated ...

Are selective endothelin-receptor antagonists really an important new advance for treating patients with treatment-resistant hypertension? The evidence from a recent study leaves us with some ...

It works by blocking the hormone endothelin from binding to receptors in blood vessels, preventing those blood vessels from constricting. Tryvio is the first endothelin receptor antagonist for ...

Ad hoc announcement pursuant to Art. 53 LR FDA confirms that prescribers and pharmacists are no longer expected to interact ...

ASCEND was a multicenter, placebo-controlled trial that aimed to investigate the effects of the endothelin-A (ET A) receptor antagonist avosentan in patients with diabetic nephropathy. The study ...

Idorsia Pharmaceuticals has claimed FDA approval for aprocitentan as a treatment for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that indication.